Human Interferon Alpha2a as Anti Hepatitis B and C
Abstract
Hepatitis is an inflammation of the liver mainly caused by hepatitis viruses. There are 5 different types of hepatitis based on the infecting virus; A, B, C, D and E. Hepatitis B and C are chronic diseases that potentially develop into hepatocarcinoma and cirrhosis on unappropriate treatments. World Health Organization (WHO) stated that currently 350 million people worldwide are living with chronic hepatitis B and 150 million people are living with Hepatitis C. The mortality rate in the world due to hepatitis is about 1.5 million people per year. The human interferon alpha2a (hIFNα2a) is a therapeutic protein used as therapeutic protein for hepatitis B and C. This review discusses the hepatitis B (HBV) and C (HCV) viruses, mechanisms of hIFNα2a as antivirus through signal transduction pathway and improvement of hIFNα2a properties by protein modification. The application of recombinant hIFNα2a (rhIFNα2a) in the treatment of hepatitis B and C that recommended by European Association for The Study of Liver (EASL) and the viral resistance mechanism are also included. The status of hepatitis B and C and the development of rhIFNα2a is also described as well.
Keywords: Antiviral, hepatitis, human interferon alpha2a, protein modification, viral resistance
Protein Interferon Alfa-2a Manusia sebagai Anti Hepatitis B dan C
Hepatitis merupakan kondisi inflamasi pada hati yang terutama disebabkan oleh virus hepatitis. Berdasarkan tipe virus yang menginfeksi, terdapat lima jenis penyakit hepatitis yaitu A, B, C, D dan E. Hepatitis B dan C merupakan penyakit kronis yang berpotensi menjadi kanker hati dan sirosis jika tidak ditangani dengan baik. World Health Organization (WHO) menyatakan bahwa saat ini terdapat 350 juta orang yang terinfeksi hepatitis B dan 150 juta orang terinfeksi hepatitis C di seluruh dunia. Angka kematian yang disebabkan hepatitis mencapai 1,5 juta orang per tahun. Protein interferon alfa-2a manusia (hIFNα2a) adalah protein terapeutik yang digunakan sebagai obat hepatitis B dan C. Review ini mendiskusikan mengenai virus hepatitis B (HBV) dan C (HCV), mekanisme hIFNα2a sebagai antivirus melalui sistem transduksi sinyal dan peningkatan sifat hIFNα2a melalui modifikasi protein. Review ini juga membahas aplikasi bentuk rekombinan hIFNα2a (rhIFNα2a) dalam penanganan hepatitis B dan C yang direkomendasikan oleh European Association for The Study of Liver (EASL) dan mekanisme resistensi virus. Status hepatitis B dan C serta perkembangan rhIFNα2a juga didiskusikan lebih lanjut.
Kata kunci: Antivirus, hepatitis, interferon alfa-2a manusia, modifikasi protein, resistensi virus
Keywords
Full Text:
PDFReferences
Chow KT, Gale M. SnapShot: Interferon signaling. Cell. 2015;163(7):1808–1808 e1. doi: 10.1016/j.cell.2015.12.008.
Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: Implications for cancer therapy. Nat Rev Cancer. 2016:16(3):131–44. doi: 10.1038/nrc.2016.14.
Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778–809. doi: 10.1128/CMR.14.4.778-809.2001
Hastings AK, Erickson JJ, Schuster JE, Boyd KL, Tollefson SJ, Johnson M, et al. Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication. J Virol. 2015:89(8):4405–20. doi: 10.1128/JVI.03275-14
Gow PJ, Mutimer DJ. Treatment of chronic hepatitis. BMJ. 2001;323:1164–7. doi: 10.1136/bmj.323.7322.1164
Ningrum RA, Wisnuwardhani PH, Santoso A, Herawati N. Antiproliferative activity of recombinant human interferon alpha2b on MCF-7 cell line. Indonesian J Pharm. 2015;26(2):86–93. doi: 10.14499/indonesianjpharm26iss2pp86
Wathon S, Budiarti S, Wisnuwardhani P, Herawati N, Santoso A, Ningrum RA. Stability of recombinant human interferon alpha2b produced in methilotropic Pichia pastoris. Int J Res Pharm Sci. 2015;6(4):312–20.
World Health Organization. WHO Health topic hepatitis [Accessed on: 3rd January 2017]. Available at: http://who.int/topics/hepatitis/en.
Beasley RP. Hepatitis b virus: The major etiology of hepatocellular carcinoma. 1987 General Motors Cancer Research Foundation Prizewinners Laureates Lectures Jack Masur Auditorium. Maryland: National Institutes of Health; 1987.
Walsh K, Alexander GJM. Update on chronic viral hepatitis. Postgrad Med J. 2017;77:498–505. doi: 10.1136/pmj.77.910.498
Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, et al. The role of hepatitis b and c viruses in hepatocellular carcinoma in a hepatitis b endemic area. Cancer. 1992;69(8):2052–4. doi: 10.1002/1097-0142(19920415)69:8<2052::AID-CNCR2820690808>3.0.CO;2-N
Beck J, Nassal M. Hepatitis b virus replication. Indian J Med Res. 2010;131:17–34.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8(3):237–49. doi: 10.1023/A:1023668705040
Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:1–10. doi: 10.1186/1743-422X-8-161.
Jayalakshmi M, Kalyanaraman N, Pitchappan R. Hepatitis b virus genetic diversity: Disease pathogenesis. Intech. 2013;69–82. doi: 10.5772/53818
The Hepatitis B Virus Database. Hepatitis b virus [Accessed on: 3rd January 2017]. Available at: https://hbvdb.ibcp.fr/HBV db/HBVdbGenome
Sharma SD. Hepatitis c virus: Molecular biology & current therapeutic options. Indian J Med Res. 2010;131:17–34.
Moradpour A, Penin F, Rice CM. Replication of hepatitis c virus. Nat Rev Microbiol. 2007;5:453–63. doi: 10.1038/nrmicro1645
Gao B, Hong F, Radaeva S. Host factors and failure of interferon α treatment in hepatitis C virus. Hepatology. 2004;39(4):880–90. doi: 10.1002/hep.20139
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–14. doi: 10.1038/nri3845
Mc Nab F, Barber KM, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. doi: 10.1038/nri3787.
Dianzani F, Baron S. Non specific defense. Medical Microbiology, 4th Edition [Accessed on: 3rd January 2017]. Available at: www.gsbs.utmb.edu/microbook/ch049.htm.
Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis b virus infection. World J Hepatol. 2015;7(11):1541–52. doi: 10.4254/wjh.v7.i11.1541.
Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. Bio Drugs. 2015;29(4):215–39. doi: 10.1007/s40259-015-0133-6.
Kanwar YS, Danesh FR, Chugh SS. Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: A historical perspective. Am J Pathol. 2007;171(1):9–13. doi: 10.2353/ajpath.2007.070356
Rajender RK, Modi MW, Pedder S. Use of peginterferon alfa-2a 40 KD (Pegasys) for the treatment of hepatitis c. Adv Drug Deli Rev. 2002;54(4):571–86.
Ceaglio N, Etcheverrigaray R, Kratje R, Oggero M. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie. 2008;90(3):437–49. doi: 10.1016/j.biochi.2007.10.013
Bielefeld P, Devilliers H, Deschasse C, Saadoun D, Sève P, Muselier A, et al. Potential of pegylated interferon alpha-2a in Behçet Uveitis: A report of five cases. Ocul Immunol Inflamm. 2016;24(5):599–602. doi: 10.3109/09273948.2015.1010652
Flintegaard TV, Thygesen P, Rahbek-Nielsen H, Levery SB, Kristensen C, Clausen H, et al. N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology. 2010;151(11):5326–36. doi: 10.1210/en.2010-0574
Miuma S, Ichikawa T, Miyaaki H, Haraguchi M, Tamada Y, Shibata H, et al. Efficacy and tolerability of pegylated interferon and ribavirin in combination with simeprevir to treat hepatitis c virus infections after living donor liver transplantation. J Interferon Cytokine Res. 2016;36(6):358–66. doi: 10.1089/jir.2015.0147
Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-α2b: A branched 40K polyethylene glycol derivative. Pharma Res. 2005;22(8)4:1374–86. doi: 10.1007/s11095-005-5278-4
Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis c. Hepat Mon. 2015;15(9):e30780. doi: 10.5812/hepatmon.30780.
El-Baky NA, Redwan EM. Therapeutic alpha-interferons protein: Structure, production, and biosimilar. Prep Biochem Biotechnol. 2015;45(2):109–27. doi: 10. 1080/10826068.2014.907175
Rachmawati H, Jessica A, Sumirtapura YC, Retnoningrum DS, Adlia A, Ningrum RA. Removing cystein group on interferon alpha 2b at position 2 and 99 does not diminish antitumor activity of the protein even better. Sci Pharm. 2016;84(1):113–30. doi: 10.3797/scipharm.ISP.2015.04
Zhao HL, Yai XQ, Xue C, Wang Y, Xiong XH, Liu ZM. Increasing the homogeneity, stability and activity of human serum albumin and interferon-a2b fusion protein by linker engineering.Protein Expr Purif. 2008;61(1):73–7. doi: 10.1016/j.pep.2008.04.013
Zhao HL, Yai XQ, Xue C, Wang Y, Xiong XH, Liu ZM. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy. Mol Pharm. 2012;9(3):664–70. doi: 10.1021/mp200347q.
Subramanian MG, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis c. Nat Biotechnol. 2007;25:1411–9. doi: 10.1038/nbt1364
European Association for the Study of the Liver. EASL clinical practice guideline: Management of chonic hepatitis b infection. J Hepatol. 2012;57(1):167–85. doi: 10.1016/j.jhep.2012.02.010
European Association For The Study Of The Liver. EASL recommendations on treatment of hepatitis c 2015. J Hepatol. doi: 2015;63(1):199–236. doi: 10.1016/j.jhep.2015.03.025
Chevaliez S, Pawlotsky JM. HCV genome and life cycle, in hepatitis c viruses genomes and molecular biology. Norfolk (UK): Horizon Bioscinces; 2006.
Pawlotsky JM, Germanidis G, Neumann A, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis c virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations. J Virol. 1998;72(4):2795–805.
Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis b virus. J Virol. 2007;81(1):159–65. doi: 10.1128/JVI.01292-06
Yue X, Wang H, Zhao F, Liu S, Wu J, Ren W, Zhu Y. Hepatitis b virus-induced calreticulin. J Immunol. 2012;189(1):279–86. doi: 10.4049/jimmunol.1103405
Kementerian Kesehatan Republik Indonesia. Situasi dan analisis hepatitis 2014, pusat data dan informasi. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.
Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis b infection in Indonesia. World J Gastroenterol. 2015;21(38):10714–20. doi: 10.3748/wjg.v21.i38.10714
Utama A, Tania NP, Dhenni R, Gani RA, Hasan I, Sanityoso A, et al. Genotype diversity of hepatitis c virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver Int. 2010;30(8):1152–60. doi: 10.1111/j.1478-3231.2010.02280.x
Pedoman pengendalian hepatitis virus. Keputusan Direktur Jenderal PP dan PL nomor: HK.03.05/D/I.4/2012
Peraturan Kepala Badan Pengawasan Obat dan Makanan Nomor 15 tahun 2015 tentang Pedoman Penilaian Produk Biosimilar.
Kementerian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia nomor HK.02.02/MENKES/52/2015. Rencana strategis kementerian kesehatan tahun 2015–2019.
Ningrum RA, Herawati N, Wardiana A. Development of higher molecular weight of recombinant human interferon alpha-2a produced in methilotropic yeast pichia pastoris. Int J Adv Sci Eng Inf Technol. 2017;7(1):8–14. doi: 10.18517/ijaseit.6.5.912.
DOI: https://doi.org/10.15416/ijcp.2017.6.4.298
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
